ODI Pharma (ODI) Q1 2025 earnings summary

Executive summary

• Net sales for the group were SEK 143,793 in Q1 2024/25, down from SEK 528,206 year-over-year.

• Net loss after financial items was SEK -1,468,183, compared to SEK -1,442,544 in the same quarter last year.

• Result per share was SEK -0.10, compared to SEK -0.09 year-over-year.

• Poland remains central to growth, with regulatory changes increasing the medical cannabis import quota for 2025.

• Rights issue proposed to raise up to SEK 4.1 million, with an additional SEK 2.0 million possible via over-allotment.

Financial highlights

• Group revenue for Q1 was SEK 251,301, down from SEK 534,301 year-over-year.

• Operating income was SEK -1,340,003, compared to SEK -1,227,369 in the prior year.

• Cash flow from operations was SEK -1,241,118, similar to SEK -1,228,452 last year.

• Total assets at quarter-end were SEK 6,076,945, down from SEK 6,796,538 year-over-year.

• No long-term liabilities; equity at quarter-end was SEK 527,078.

Outlook and guidance

• Increased Polish import quota for medical cannabis expected to drive revenue growth in coming quarters.

• Rights issue, if fully subscribed, will provide capital to sustain operations until cash flow positivity.

• Expansion efforts focused on Poland and new European markets.